1. Class action filed against Iovance for misleading investor communications. 2. Revenue guidance slashed from $450M-$475M to $250M-$300M for 2025. 3. Quarterly product revenue fell from $73.7M to $49.3M in Q1 2025. 4. ATCs faced delays and inefficiencies affecting patient treatment rates. 5. Iovance stock dropped 44.8% to $1.75 after revenue announcement.
The significant revenue guidance cut suggests a dire outlook, which historically results in steep price declines. Similar instances have seen stocks plummet sharply following poor performance forecasts.
The ongoing class action and revenue drop directly impact IOVA's valuation and investor trust. Legal issues can exacerbate market perception and stock performance.
Given the immediate financial result disclosures, investor confidence will likely be shaken in the short-term. Historical patterns show sharp reactions to poor quarterly results.
Robbins LLP informs stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025. Iovance is a commercial-stage biopharmaceutical company which develops and commercializes cell therapies for the treatment of metastatic melanoma and other solid tumor cancers.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
Robbins LLP is Investigating Allegations that Iovance Biotherapeutics, Inc. (IOVA) Misled Investors Regarding its Business Prospects
According to the complaint, during the class period, defendants failed to disclose that: (1) new Authorized Treatment Centers ("ATCs") were experiencing longer timelines to begin treating patients with Amtagvi; (2) the Company's sales team and new ATCs were ineffective in patient identification and patient selection for Amtagvi, leading to higher patient drop-offs; (3) the foregoing dynamics led to higher costs and lower revenue because ATCs could not keep pace with manufactured product; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
On May 8, 2025, Iovance released its first quarter 2025 financial results, revealing a quarterly total product revenue of $49.3 million, a significant decline from the prior quarter's $73.7 million. The Company also announced its full fiscal year 2025 total product revenue guidance had been slashed from $450 million - $475 million to $250 million - $300 million, a reduction of over 40% at the midpoint. The Company revealed it was "revising full-year 2025 revenue guidance to reflect recent launch dynamics" of Amtagvi. The Company further revealed "[t]he updated forecast considers experience with ATC [authorized treatment center] growth trajectories and treatment timelines for new ATCs." On this news, the price of Iovance shares declined $1.42 per share, or 44.8%, to close at $1.75 per share on May 9, 2025.
You may be eligible to participate in the class action against Iovance Biotherapeutics, Inc. Shareholders who want to serve as lead plaintiff for the class are required to file their papers with the court by July 14, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.
To be notified if a class action against Iovance Biotherapeutics, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
SOURCE Robbins LLP